Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
ClinicalTrials.gov record
Recruiting Phase 2 Interventional

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

ClinicalTrials.gov ID: NCT05061550

Public ClinicalTrials.gov record NCT05061550. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced Sep 1, 2026, 7:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combination with Durvalumab or Rilvegostomig and single agent platinum chemotherapy in participants with resectable, early-stage non-small cell lung cancer.

Study identification

NCT ID
NCT05061550
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
AstraZeneca
Industry
Enrollment
630 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 95 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 13, 2022
Primary completion
May 27, 2030
Completion
May 27, 2030
Last update posted
Aug 20, 2026

2022 – 2030

United States locations

U.S. sites
24
U.S. states
17
U.S. cities
21
Facility City State ZIP Site status
Research Site Little Rock Arkansas 72205 Recruiting
Research Site Los Angeles California 90095 Recruiting
Research Site Oakland California 94611 Withdrawn
Research Site New Haven Connecticut 06510 Recruiting
Research Site Stuart Florida 34994 Completed
Research Site Gainesville Georgia 30501 Completed
Research Site Chicago Illinois 60637 Recruiting
Research Site Baltimore Maryland 21201 Withdrawn
Research Site Baltimore Maryland 21231 Recruiting
Research Site Boston Massachusetts 02215 Recruiting
Research Site Saint Louis Park Minnesota 55426 Completed
Research Site Omaha Nebraska 68124 Recruiting
Research Site Buffalo New York 14263 Recruiting
Research Site Cleveland Ohio 44195 Recruiting
Research Site Pittsburgh Pennsylvania 15212 Recruiting
Research Site Chattanooga Tennessee 37404 Recruiting
Research Site Memphis Tennessee 38120 Recruiting
Research Site Nashville Tennessee 37203 Recruiting
Research Site Nashville Tennessee 37232 Recruiting
Research Site Houston Texas 77030 Recruiting
Research Site Houston Texas 77090 Recruiting
Research Site Fairfax Virginia 22031 Recruiting
Research Site Edmonds Washington 98026 Recruiting
Research Site Seattle Washington 98104 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 71 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05061550, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 20, 2026 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05061550 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →